LACTOLOGY FOUNDATION

This monograph summarizes toxicological and lactational aspects of medicines classified under ATC A03CB04 (methylhomatropine bromide and psycholeptics) for use as web page content.medpedia.framar+2

ATC class overview

ATC A03CB04 belongs to the subgroup “Belladonna and derivatives in combination with psycholeptics” within drugs for functional gastrointestinal disorders.atcddd.fhi+2
The active antispasmodic component is homatropine methylbromide (methylhomatropine bromide), a quaternary ammonium antimuscarinic, combined with sedative psycholeptic agents.drugbank+2

Pharmacological profile

Homatropine methylbromide is a peripherally acting muscarinic acetylcholine receptor antagonist that inhibits parasympathetic activity in smooth muscle, particularly in the gastrointestinal and biliary tract.wikipedia+2
Because it is permanently charged, it does not cross the blood–brain barrier, which limits central nervous system effects compared with tertiary anticholinergics such as atropine.drugbank+1

Psycholeptics in these combinations are centrally acting drugs with sedative and anxiolytic properties that reduce psychomotor agitation and subjective distress associated with painful spasms.who+1
The combined preparations are used to relieve intestinal spasms, abdominal cramps, and biliary colic, and may be co‑administered with antacids or other ulcer therapies.drugs.ncats+2

Clinical indications

Medicines in A03CB04 are indicated for functional gastrointestinal disorders characterized by smooth‑muscle hypertonia, such as irritable bowel‑type colicky pains, spasmodic biliary disorders, and peptic or duodenal ulcer–related spasm.wikipedia+2
The antispasmodic component decreases strong peristalsis and smooth‑muscle tone, while the psycholeptic component provides symptomatic relief of anxiety and tension accompanying colicky pain episodes.medpedia.framar+2

In some markets, low-dose homatropine methylbromide is also included in combination cough and analgesic preparations to discourage overdose, although those products may be classified under different ATC codes.drugs.ncats+1
Within A03CB04, however, the primary therapeutic focus is on gastrointestinal and biliary colic rather than respiratory indications.atcddd.fhi+1

Contraindications and precautions

Use of methylhomatropine–psycholeptic combinations is contraindicated in untreated narrow‑angle glaucoma due to the risk of precipitating acute angle closure through antimuscarinic pupil dilation.wikipedia+1
They are also contraindicated in myasthenia gravis, where further cholinergic blockade can exacerbate skeletal muscle weakness.wikipedia+2

Additional contraindications include severe heart failure and thyrotoxicosis, because anticholinergic effects and certain psycholeptics can worsen tachycardia and hemodynamic instability.medpedia.framar+1
Hypersensitivity to methylhomatropine, belladonna derivatives, or the specific psycholeptic component is a further absolute contraindication.gsrs.ncats.nih+1

Caution is required in elderly patients, those with prostatic hypertrophy, chronic constipation, or autonomic neuropathy, in whom peripheral anticholinergic effects may precipitate urinary retention or paralytic ileus.drugbank+2
Patients with existing psychiatric or neurological disease may also experience additive central effects from the psycholeptic component and should be monitored closely.who+1

Toxicological considerations

The toxic profile of methylhomatropine bromide is qualitatively similar to that of atropine, reflecting its parasympatholytic mechanism, although central toxicity is typically reduced due to poor penetration of the blood–brain barrier.wikipedia+1
Acute overdose may present with a classic anticholinergic syndrome: dry mucous membranes, hyperthermia, tachycardia, mydriasis with blurred vision, urinary retention, ileus, and, at high doses or when combined with other centrally acting drugs, agitation or confusion.wikipedia+1

Psycholeptics contribute additional dose‑dependent risks, including excessive sedation, respiratory depression (for some agents), hypotension, and impaired psychomotor performance, especially when combined with alcohol or other CNS depressants.who+1
Chronic use may be associated with tolerance, dependence, or withdrawal phenomena depending on the psycholeptic class (e.g. benzodiazepine‑type sedatives), which must be taken into account in risk assessment.drugbank+1

From a comparative standpoint, peripheral toxicity (cardiovascular and gastrointestinal) is driven mainly by the antimuscarinic component, whereas neuropsychiatric toxicity is dominated by the psycholeptic component and by any co‑administered sedatives or opioids.wikipedia+1
Thus, total toxic burden depends on the full combination, not solely on methylhomatropine, and evaluation should consider patient comorbidities and concomitant medications.who+1

Lactation and breastfeeding safety

Homatropine methylbromide is a quaternary ammonium compound with limited oral bioavailability and minimal transfer across biological membranes, suggesting low passage into breast milk and poor systemic absorption in the breastfed infant.drugbank+1
However, robust human pharmacokinetic data during lactation are scarce, so the assessment must extrapolate from physicochemical properties and related antimuscarinic agents.who+1

Peripheral anticholinergic effects in the mother—such as reduced GI motility, urinary retention, or tachycardia—do not directly compromise milk production, but pronounced anticholinergic load could theoretically reduce secretory flow or contribute to dehydration.wikipedia+1
Short‑term, low‑dose use for acute colic in a healthy postpartum woman is therefore unlikely to pose major lactational risk, provided maternal side effects are minimal and infant clinical status is monitored.wikipedia+1

Psycholeptics in A03CB04 raise more significant lactational concerns because many sedatives and anxiolytics can accumulate in breast milk to varying degrees and may cause sedation, poor feeding, or hypotonia in the infant.drugbank+1
Risk varies by specific psycholeptic (e.g. benzodiazepine vs. older sedative), so combinations should generally be avoided for routine use during breastfeeding unless a particular component is well‑documented as compatible and infant monitoring is ensured.who+1

For toxicological‑lactological classification, A03CB04 medicines may be considered “cautiously usable in lactation” only for brief, intermittent treatment when safer alternatives are unsuitable, with preference for the lowest effective dose and psycholeptics with favorable lactation data.drugbank+1
In high‑risk infants (premature, underlying cardiopulmonary or neurologic disease) and when long‑term therapy is anticipated, non‑sedative antispasmodic options without psycholeptics are preferable.who+1

Clinical use and monitoring in lactating patients

In breastfeeding women, use of A03CB04 combinations should follow a strict indication, such as severe biliary colic not controlled with non‑sedating antispasmodics or analgesics.medpedia.framar+1
Before prescribing, clinicians should evaluate maternal comorbidities (cardiovascular, ophthalmologic, neuromuscular, thyroid) to avoid contraindicated situations and minimize anticholinergic burden.medpedia.framar+2

When short‑course therapy is given, infants should be observed for signs of excessive sedation, feeding difficulties, decreased weight gain, or unusual constipation, which could indicate significant exposure to psycholeptics or anticholinergics via breast milk.drugbank+1
If such signs appear, breastfeeding may need temporary interruption or the medicine discontinued, with consideration of alternative therapies and lactation‑compatible analgesia or antispasmodics.who+1

Dose and timing strategies can modestly reduce infant exposure—for example, taking the dose immediately after breastfeeding or before the longest sleep interval, assuming the psycholeptic’s peak levels and half‑life allow meaningful reduction.drugbank+1
Nonetheless, due to limited compound‑specific lactation data for methylhomatropine combinations, any use remains a risk‑managed decision that should be revisited regularly.who+1

Regulatory and prescribing information

WHO ATC/DDD tools list A03CB04 as “homatropine methylbromide and psycholeptics,” classified under drugs for functional gastrointestinal disorders, with dosing recommendations defined per route of administration and indication.iris.who+2
Products in this class are generally available on prescription only, reflecting the need for professional assessment of contraindications, interactions, and potential CNS effects from psycholeptics.medpedia.framar+2

National formularies may differ in exact combinations registered under A03CB04, and some markets have limited availability of methylhomatropine‑based products due to changes in prescribing patterns and the introduction of newer agents.drugcentral+2
Clinicians should therefore consult local product information and lactation resources to verify the psycholeptic component and its safety profile before use in breastfeeding women.drugbank+1